Aggressive Squamous Cell Carcinoma of Unknown Primary: Isolated Inguinal Metastasis and Uncommon Progression.

Publisher: International Scientific Information, Inc Country of Publication: United States NLM ID: 101489566 Publication Model: Electronic Cited Medium: Internet ISSN: 1941-5923 (Electronic) Linking ISSN: 19415923 NLM ISO Abbreviation: Am J Case Rep Subsets: MEDLINE

Publication: <2014- > : Smithtown, NY : International Scientific Information, Inc.
Original Publication: Albertson, NY : International Scientific Literature, Inc.

Neoplasms, Unknown Primary*/pathology ; Neoplasms, Unknown Primary*/therapy ; Carcinoma, Squamous Cell*/secondary ; Carcinoma, Squamous Cell*/therapy; Humans ; Female ; Aged ; Lymphatic Metastasis ; Fatal Outcome ; Disease Progression ; Inguinal Canal ; Lung Neoplasms/secondary

BACKGROUND Carcinoma of unknown primary (CUP) is a rare malignancy, accounting for less than 5% of all cancers. Inguinal lymph node (LN) metastasis is an uncommon presentation, with squamous cell carcinoma (SCC) comprising a small subset of CUP cases. CASE REPORT A 65-year-old woman presented with a left inguinal mass, which was confirmed as SCC. Comprehensive diagnostics, including PET-CT, failed to identify a primary tumor. Following initial surgical resection, she experienced local recurrence and was treated with chemoradiotherapy (CRT), receiving 45 Gy to potential primary and nodal sites, followed by a 59.4 Gy boost and concurrent cisplatin. Despite an initial response to treatment, the disease progressed aggressively, leading to lung metastases and a subcutaneous metastatic nodule in the pubic region. After chemotherapy with cisplatin and 5-fluorouracil, 2 nodular lesions were identified in the right breast as new metastases - a finding not previously documented in the literature. Despite plans for a biopsy of the right breast lesions, the patient died due to respiratory complications 12 months after diagnosis. CONCLUSIONS This case of isolated inguinal LN metastasis from SCC of an unknown primary highlights the unpredictable and aggressive nature of CUP, even in subtypes typically considered favorable. The findings suggest that more aggressive multimodal treatment approaches may be warranted to manage and control potential microscopic disease effectively. Reevaluating standard treatment protocols for such presentations is essential to improve patient outcomes.

J Plast Reconstr Aesthet Surg. 2006;59(5):547-9. (PMID: 16631563)
Clin Transl Oncol. 2022 Apr;24(4):681-692. (PMID: 35320504)
Semin Oncol. 2009 Feb;36(1):44-51. (PMID: 19179187)
Cancer. 1978 Mar;41(3):919-23. (PMID: 638977)
Crit Rev Oncol Hematol. 2012 Oct;84(1):85-92. (PMID: 22386806)
J Gynecol Oncol. 2008 Jun;19(2):145-9. (PMID: 19471557)
J Nippon Med Sch. 2022 Aug 27;89(4):454-459. (PMID: 33867427)
Eur J Cancer. 2021 Nov;157:179-189. (PMID: 34521064)
Clin Transl Oncol. 2018 Jan;20(1):89-96. (PMID: 29230692)
Pract Radiat Oncol. 2014 Nov-Dec;4(6):404-8. (PMID: 25407862)
Cancer. 1987 Feb 1;59(3):572-7. (PMID: 3791166)
Cancer Epidemiol. 2014 Jun;38(3):227-34. (PMID: 24726751)
Taiwan J Obstet Gynecol. 2024 Jan;63(1):85-89. (PMID: 38216277)
Ann Oncol. 2023 Mar;34(3):228-246. (PMID: 36563965)
Ann Oncol. 2015 Sep;26 Suppl 5:v133-8. (PMID: 26314775)
Semin Diagn Pathol. 2018 May;35(3):199-206. (PMID: 29203116)
Eur J Cancer. 2003 Sep;39(14):1990-2005. (PMID: 12957453)
Ann Oncol. 2012 Jul;23(7):1854-63. (PMID: 22115926)
Cancer Epidemiol. 2019 Aug;61:139-141. (PMID: 31254795)
Scand J Urol. 2015 Feb;49(1):79-80. (PMID: 25313619)

Date Created: 20250415 Date Completed: 20250415 Latest Revision: 20250420

20250420

PMC12007562

10.12659/AJCR.946689

40230005